Findings from a Phase III trial of azacitidine and venetoclax plus pevonedistat in AML

Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, comments on the results of a Phase III trial combining azacitidine and venetoclax with pevonedistat in patients with newly diagnosed acute myeloid leukemia (AML). The combination was well-tolerated, but it did not demonstrate superiority in overall survival. However, the trial did show significant activity in a subset of patients with IDH mutations, a crucial finding given the lack of available IDH inhibitors in many countries. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Findings from a Phase III trial of azacitidine and venetoclax plus pevonedistat in AML канала VJHemOnc – Video Journal of Hematology & HemOnc
Speaker: Cristina Papayannidis, Institution: University of Bologna, Event: ISAL 2025, Format: Interview, Subject: Acute Myeloid Leukemia, Subject: Leukemia, Field: Treatment, Field: Trial Updates, Medicines: Venetoclax, Medicines: Azacitidine, Medicines: Pevonedistat, IDH mutations, AML, IDH inhibitors